Tumor Necrosis Factor Inhibitors

TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% compared with NSAIDs, according to data published in Arthritis & Rheumatology.

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with rheumatoid arthritis-associated interstitial lung disease, according to data published in The Lancet Rheumatology.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.

WASHINGTON — In this video, Micaela F. Bayard, MD, highlights a conversation on the evolution of biosimilars from ACR Convergence 2024.

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

TNF inhibitors have similar rates of adverse events and treatment response in ankylosing spondylitis regardless of whether the disease developed early or late in life, according to data published in Scientific Reports.

Greater adherence to TNF inhibitor therapy for rheumatoid arthritis led to fewer adverse events, with the optimal adherence threshold being approximately 60% of days covered, according to data published in Clinical Rheumatology.

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

Both ustekinumab and TNF inhibitors demonstrate significant improvement in psoriatic arthritis disease activity, with similar positive results in minimal and low disease activity, and remission, after 6 months, according to data.